Molina reports higher-than-feared Medicaid costs; shares tumble

Reuters
06 Feb
Molina reports higher-than-feared Medicaid costs; shares tumble

Feb 5 (Reuters) - Molina Healthcare MOH.N reported higher-than-expected costs tied to its government-backed Medicaid plans, sending the health insurer's shares down nearly 9% in after-hours trading.

The end of a pandemic-era federal policy and redetermination of Medicaid eligibility by states have made insurers face higher costs for over a year, marking an uptick in sicker patients.

Long Beach, California-based Molina's quarterly medical cost ratio, the percentage of premiums paid out for medical services, was 90.2%, higher than estimates of 88.43%, as per data compiled by LSEG.

Molina served about 4.89 million people through its Medicaid plans as of Dec. 31, an increase of 7.66% compared to the previous year.

Larger peers Centene Corp CNC.N and UnitedHealth Group UNH.N have also reported higher medical costs tied to the end of the pandemic-era federal policy.

Molina expects its 2025 total revenue to be $44 billion, with adjusted profit of at least $24.5 per share. Analysts on average had expected full-year revenue of $43.52 billion and adjusted profit of $25.71 per share.

Molina posted quarterly premium revenue of $9.98 billion. Its total revenue of $10.5 billion was above analysts' estimates of $10.32 billion.

The health insurer posted a fourth-quarter adjusted profit of $5.05 per share, below Wall Street estimates of $5.72.

(Reporting by Unnamalai L in Bengaluru; Editing by Maju Samuel)

((Unnamalai.L@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10